Systemischer Lupus Erythematodes (SLE)

Hunnangkul S, Nitsch D, Rhodes B, Chadha S, Roberton CA, Pessoa-Lopes P, et al (2008) Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus. Arthritis Rheum 58: 1116–1124 Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al (2010) Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 16: 47–57 Hahn BH, Ebling F, Singh RR, Singh RP, Karpouzas G, La Cava A (2005) Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 1051: 433–441 Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349: 1526–1533 Munoz LE, Janko C, Grossmayer GE, Frey B, Voll RE, Kern P, et al (2009) Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 60: 1733–1742 Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61: 1168–1178 Bonelli M, Smolen JS, Scheinecker C (2010) Treg and lupus. Ann Rheum Dis 69 [Suppl 1]: i65–66 Klinman DM, Steinberg AD (1995) Inquiry into murine and human lupus. Immunol Rev 144: 157–193 Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al (2005) Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 175: 8392–8400 Toussirot E, Roudier J (2008) Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 22: 883–896 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271–1277 McKinley PS, Ouellette SC, Winkel GH (1995) The contributions of disease activity, sleep patterns, and depression to fatigue in systemic lupus erythematosus. A proposed model. Arthritis Rheum 38: 826–834 Santiago MB, Galvao V (2008) Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature. Medicine (Baltimore) 87: 37–44 Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15: 241–250 The Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324: 150–154 Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62: 863–868 Wilson K, Abeles M (1994) A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 21: 1674–1677 Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC (2006) Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 65: 417–418 Grossman JM (2009) Lupus arthritis. Best Pract Res Clin Rheumatol 23: 495–506 Barile L, Lavalle C (1992) Transverse myelitis in systemic lupus erythematosus – the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol 19: 370–372 Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121–2131 Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971–980 Looney RJ, Anolik J, Sanz I (2010) A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 20: 1–10 Looney RJ (2010) B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 70: 529–540 Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62: 542–552 Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal LH, Becker JC, Kelly S, et al (2009) Activity of Abatacept in SLE: Results of a 12-month phase II exploratory study. Annual European Congress of Rheumatology (EULAR), 2009 Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS, et al (2007) Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 56: 274–279